BioCentury
ARTICLE | Company News

EMA to review GSK's malaria vaccine

July 24, 2014 11:55 PM UTC

EMA accepted for review an MAA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for its RTS,S malaria vaccine -- moving the product closer to being the first vaccine approved to prevent malaria infection in infants and children. There are currently no approved vaccines for malaria. A positive EMA opinion on the MAA would be the basis for regulatory applications for RTS,S in countries in sub-Saharan Africa, which accounts for about 90% of annual malaria deaths. GSK said it does not expect a decision on the vaccine until next year. Pending EMA's decision, GSK said the World Health Organization also could issue an immunization policy recommendation for RTS,S by the end of 2015. ...